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ORIGINAL RESEARCH

Vascular endothelial growth factor receptor 3 signaling contributes
to angioobliterative pulmonary hypertension
Ayser Al-Husseini,1 Donatas Kraskauskas,1 Eleanora Mezzaroma,2 Andrea Nordio,2
Daniela Farkas,1 Jennifer I. Drake,1 Antonio Abbate,2 Quentin Felty,3 Norbert F. Voelkel1
1

Victoria Johnson Laboratory for Lung Research, Virginia Commonwealth University, Richmond, Virginia, USA; 2VCU Pauley Heart
Center, Virginia Commonwealth University, Richmond, Virginia, USA; 3Department of Environmental and Occupational Health,
Florida International University, Miami, Florida, USA

Abstract: The mechanisms involved in the development of severe angioobliterative pulmonary arterial hypertension (PAH) are multicellular and complex. Many of the features of human severe PAH, including angioobliteration, lung perivascular inflammation, and right heart failure, are reproduced in the Sugen 5416/
chronic hypoxia (SuHx) rat model. Here we address, at first glance, the confusing and paradoxical aspect of
the model, namely, that treatment of rats with the antiangiogenic vascular endothelial growth factor (VEGF)
receptor 1 and 2 kinase inhibitor, Sugen 5416, when combined with chronic hypoxia, causes angioproliferative
pulmonary vascular disease. We postulated that signaling through the unblocked VEGF receptor VEGFR3 (or
flt4) could account for some of the pulmonary arteriolar lumen–occluding cell growth. We also considered
that Sugen 5416–induced VEGFR1 and VEGFR2 blockade could alter the expression pattern of VEGF isoform
proteins. Indeed, in the lungs of SuHx rats we found increased expression of the ligand proteins VEGF-C and
VEGF-D as well as enhanced expression of the VEGFR3 protein. In contrast, in the failing right ventricle of
SuHx rats there was a profound decrease in the expression of VEGF-B and VEGF-D in addition to the previously described reduction in VEGF-A expression. MAZ51, an inhibitor of VEGFR3 phosphorylation and
VEGFR3 signaling, largely prevented the development of angioobliteration in the SuHx model; however,
obliterated vessels did not reopen when animals with established PAH were treated with the VEGFR3 inhibitor. Part of the mechanism of vasoobliteration in the SuHx model occurs via VEGFR3. VEGFR1/VEGFR2
inhibition can be initially antiangiogenic by inducing lung vessel endothelial cell apoptosis; however, it can be
subsequently angiogenic via VEGF-C and VEGF-D signaling through VEGFR3.
Keywords: Sugen 5416, chronic hypoxia, VEGF isoforms, VEGF receptor 3, sFlt-1, MAZ51, right heart
failure, capillary rarefaction.
Pulm Circ 2015;5(1):101-116. DOI: 10.1086/679704.

I NT RO D UCT I ON
It is now well recognized that the pathobiology of severe
forms of pulmonary arterial hypertension (PAH) is driven
by a process that is multicellular and highly complex.1
Resident lung vascular cells, inflammatory cells and cells
of the immune system, bone marrow–derived cells, and
various precursor or stem cells are all potential participants in the sequence of events leading to vascular remodeling; their particular and interactive roles in pulmonary vascular remodeling are under active investigation
in a number of experimental models of PAH.2-6 The concepts of apoptosis resistance of proliferating vascular cells1,7
and of misguided angiogenesis have now advanced the

field, and we have proposed that angioobliterative PAH is
initiated by pulmonary vascular endothelial cell apoptosis. However, by itself endothelial cell apoptosis is insufficient to cause severe PAH. Instead, apoptosis-resistant
cells emerge and proliferate, ultimately leading to vessel
lumen obliteration,1 perhaps aided by the weakening of a
bone morphogenetic protein receptor type 2–dependent
homeostatic control of pulmonary arteriolar wall injuryrepair mechanisms.8
To investigate these mechanisms of lung vessel injury
and repair, rat models of severe angioobliterative PAH
and right heart failure,9,10 which are based on chronic hyp-
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oxic exposure11 or immunoinsufficiency5 together—and
very paradoxically—with the administration of an antiangiogenic vascular endothelial growth factor (VEGF) inhibitor, are now being examined.8,12
This apparent paradox of antiangiogenic drug–induced
PAH can now be explained by taking into account an improved understanding of the role played by VEGF in vascular biology13-15 and of the mechanisms of resistance of
tumor cells to antiangiogenic drugs.16,17 Collectively, a
large number of new studies illustrate the multitude of
biological effects that are attributable to VEGF-A, its various splice variants, and signals transmitted via several
membrane and nuclear VEGF receptors.18-24
Although it has been shown that the potent endothelial
cell growth factor VEGF and its receptor VEGFR2 (KDR)
are highly expressed in lung vascular lesions of patients
with idiopathic PAH (IPAH),25 it remains unclear whether
and how VEGF actually drives pulmonary angioproliferation in severe forms of human PAH. Certainly, the presence of elements that may participate in the pathobiological processes can be demonstrated by examining tissue
samples from IPAH patients. However, such studies cannot explain disease mechanisms; thus, these studies need
to be complemented by the interrogation of animal models
of PAH.
To begin this interrogation, we here examine the
Sugen 5416/chronic hypoxia (SuHx) rat model of severe
angioobliterative PAH and address the question whether
VEGF, in spite of the blockade of the receptors VEGFR1
and VEGFR2 by Sugen 5416, contributes to the pathogenesis of PAH in this model. Because Sugen 5416 inhibits the intracellular VEGFRI and VEGFRII tyrosine
kinases, we wondered whether the lymphangiogenic and
angiogenic VEGFR3 and its ligands VEGF-C and VEGFD26-31 are expressed in the lungs of animals with PAH
and whether the VEGFR3 blocker MAZ5132,33 ameliorates the development of severe PAH in SuHx animals.
Our experiments show that a change in the VEGF isoform and VEGF receptor expression pattern occurs in the
lungs and hearts of SuHx-treated pulmonary hypertensive
rats and that signaling via the overexpressed VEGFR3
(flt4) contributes to the development of angioobliterative
PAH. In the SuHx rat model, severe PAH is associated
with right heart failure34 and, in contrast to the cell proliferation that occludes the lung vessels, there is a right
ventricular loss of microvessels, or capillary rarefaction.
We have reported that this right ventricle (RV) capillary
rarefaction is associated with a decreased myocardial expression of VEGF-A.35 Now we show that the expression
of the VEGF-B splice variant36-38 is likewise decreased in

the tissues of failing rat RVs, further supporting the hypothesis that loss of expression of angiogenesis factors
can explain the capillary rarefaction35,39 in failing RVs.34
METHODS
Animal models
All experiments were approved by the Institutional Animal Care and Use Committee of Virginia Commonwealth
University. Pulmonary hypertension was induced in male
Sprague-Dawley rats (body weight, 250 g) as follows: the
animals received a single subcutaneous injection of the
VEGF receptor tyrosine kinase inhibitor (Sugen 5416,
20 mg/kg) and were exposed to chronic hypoxia for 4 weeks
(SuHx model), as described elsewhere.11 Age- and sexmatched rats were exposed to 10% hypoxia for 4 weeks
in the prevention studies and for 4 weeks followed by a
return to room air for 2 weeks in the intervention studies. For hypoxia-only and control animals, age- and sexmatched rats were placed in the hypoxic chambers at
room air, consecutively, for the same period of time as the
other groups. MAZ51 (8 mg/kg; purchased from Calbiochem/EMD Millipore, San Diego, CA; 676492-10MG) was
dissolved in carboxymethyl cellulose and administered
subcutaneously every other day for 21 days.32 At the end
of the exposure period, each rat was anesthetized with an
intramuscular injection of ketamine/xylazine. The thoracic cavities were opened by midline incision, and hemodynamic measurements were obtained using a 4.5-mm
conductance catheter (Millar Instruments, Houston, TX)
and the PowerLab data acquisition system (AD Instruments, Colorado Springs, CO). The right lung was removed and frozen in liquid nitrogen. The left lung was
inflated with 0.5% low-melting agarose at a constant pressure of 25 cm of H2O, fixed in 10% formalin for 48 hours,
and used for immunohistochemistry (IHC) analysis. Right
ventricular hypertrophy was measured as the ratio of right
ventricular weight to left ventricular plus septal weight
(RV/LVþS).

Antibodies and enzyme-linked immunosorbent
assay (ELISA)
We used the following antibodies: rabbit anti-VEGF-A,
rabbit anti-VEGF-D, mouse anti-SPARC (Santa Cruz Biotechnology, Santa Cruz, CA), rabbit anti-VEGF-B, goat
anti-VEGFR2 (Abcam, Cambridge, United Kingdom), rabbit anti-VEGF-C, rabbit anti-VEGFR3 (Novus Biologicals,
Littleton, CO), rabbit anti-tubulin (Cell Signaling, Beverly,
MA), and mouse anti-β-actin (Sigma, St. Louis, MO). The
ELISA for measuring rat sFlt-1 was purchased from Mybiosource (San Diego, CA; MBS007319).
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Western blot analysis
Whole-cell lysate from one lobe of the right lung was prepared using radioimmunoprecipitation assay buffer (Sigma),
and the protein concentration was determined using the
Bio-Rad Protein DC Protein Assay (Bio-Rad, Hercules, CA).
Whole cellular protein (35 μg/lane) was separated by sodium
dodecyl sulfate (SDS) polyacrylamide gel electrophoresis
with 4%–12% Bis-Tris Nupage gel (2-(N-morpholino)
ethanesulfonic acid [MES] SDS running buffer) and blotted onto a polyvinylidene difluoride membrane. The membrane was incubated with blocking buffer (5% nonfat dry
milk/phosphate-buffered saline [PBS] 0.1% Tween 20) at
room temperature for 1 hour. Overnight at 4°C the membrane was then probed with the primary antibodies diluted in blocking buffer. Subsequently, membranes were
incubated with horseradish peroxidase–conjugated antimouse or anti-rabbit antibody diluted 1 ∶ 5000 in blocking
buffer. Blots were developed with enhanced chemiluminescence (PerkinElmer, Waltham, MA) on GeneMate Blue
Basic Autorad Films (BioExpress, Kaysville, UT). Blots were
scanned and densitometry analysis was performed using
ImageJ (National Institutes of Health, Bethesda, MD;
http://imagej.nih.gov/ij/).
Statistical analysis
Data are presented as mean  SEM. Two groups were
compared with the two-tailed unpaired Student’s t test,
and more than two groups were compared with one-way
analysis of variance followed by the Neuman-Keuls multiple comparison test. Statistical tests were performed
and graphs were created with GraphPad Prism (ver. 5.0;
GraphPad Software, San Diego, CA). Differences with
P < 0.05 were considered significant.
Histology and microscopy
Lung tissue sections (4-μm paraffin sections) were used
for staining; slides were incubated overnight with antiVEGF-C rabbit antibody (1 ∶ 50 dilution) and anti-VEGFR3
rabbit antibody (1 ∶ 50 dilution). For counting the number
of VEGFR3þ luminal vascular cells, 10 random pulmonary arteries per tissue section stained with the antiVEGFR3 antibody were captured at 40 magnification,
and then the number of VEGFR3þ cells in the lumen of
pulmonary vessels was counted.
For immunofluorescence (IF) and IHC stainings, 3-μm
sections were rehydrated, which was followed by antigen
retrieval with heat in citrate buffer (pH 6.0) for 20 min.
Then, sections were blocked with 1% normal sheep serum (NSS)/PBS for 15 min and incubated with primary
antibody 1 in 1% NSS in PBS overnight at 4°C. Sections
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were then incubated with secondary antibody 1 in PBS
for 4 hours. For double IF staining, additional sequential
incubations were performed with primary and secondary
antibody 2 similar to 1. Finally, the sections were counterstained with 4′,6-diamidino-2-phenylindole (DAPI) at
1 ∶ 20,000 for 5 minutes and mounted in SlowFade Gold
(both Life Technologies/Invitrogen, Carlsbad, CA). For all
IHC and IF stainings, controls with unspecific immunoglobulin G were run in parallel with each staining batch
and treatment group.

Assessment of angioproliferative vascular lesions,
perivascular inflammation, and the bronchusassociated lymphoid tissue (BALT) area
A quantitative analysis of luminal obstruction was conducted first by taking 10 random images per lung section
from each rat and then counting the small pulmonary
arteries (external diameter, <50 um), performed by two
investigators blinded to treatment group. Vessels were
assessed to grade for angioobliteration from two random
left lung slices: no evidence of angioproliferation (open),
partially obliterated (<50%), and full-luminal occlusion
(obliterated).
For the purpose of assessing perivascular inflammation, fields were selected as described for the determination of the number of obliterated vessels. The perivascular
infiltrate surrounding each pulmonary artery was quantified as follows: 0: absent, 1: minimal with a single layer
clustering of inflammatory cells; 2: moderate, with localized clustering of inflammatory cells; and 3: abundant,
with large clusters of inflammatory cells extending from
the perivascular region toward adjacent alveoli. The final
inflammatory score was the result of the following: [0  n
vessels with 0 score þ 1  n vessels with score of 1 þ 2 
n vessels with score of 2 þ 3  n vessels with score of
3]/number of analyzed vessels, as described elsewhere;40
100  36 vessels were examined per lung.
The BALT area was measured by analyzing 10 sections
per group using AxioVision software (Zeiss, Oberkochen,
Germany); an outline was drawn by manual placement
and measured by planimetry.
RNA isolation
Total RNA was isolated from ∼30 mg of snap-frozen rat
heart and lung tissue using the Qiagen RNeasy Mini Kit
(Qiagen, Valencia, CA). Tissues were homogenized with
Buffer RLT and β-mercaptoethanol in an MP FastPrep24 Lysing Matrix D tube (MP Biomedicals, Solon, OH),
and RNA was isolated and purified in accordance with
the manufacturer’s protocol. Concentration of RNA was

104

| Role of VEGFR3 in angioobliterative PAH

Al-Husseini et al.

calculated with a NanoDrop ND-1000 spectrophotometer
(Thermo Fisher Scientific, Wilmington, DE). All samples
had an A260/A280 ratio between 1.9 and 2.1.

Microarray analysis
The amplification and hybridization process was as follows: 500 ng of total RNA was amplified and labeled with
cyanine 5 (Cy5) and 500 ng of universal rat reference
RNA (Stratagene, Santa Clara, CA) was amplified and labeled with cyanine 3 (Cy3) using the Agilent QuickAmp
Labeling Kit (Agilent Technologies, Santa Clara, CA) to
produce labeled complementary RNA (cRNA) in accordance with the manufacturer’s protocol. After amplification and labeling, the dye incorporation was determined
with a NanoDrop ND-1000 spectrophotometer (Thermo
Fisher Scientific). All ratios were >8.0 pmol dye/μg cRNA,
per the manufacturer’s recommendation. We combined
825 ng of sample and 825 ng of reference RNA and incubated that with an Agilent whole-rat genome 4  44k
microarray slide (Agilent Technologies, Wilmington, DE)
for 17 hours at 65°C. After hybridization, slides were washed
in accordance with the manufacturer’s protocol and scanned
with an Axon GenePix 4200A scanner (Axon Instruments,
Union City, CA) at a resolution of 5 μM.
Raw expression data files were uploaded into R (R Development Core Team, Vienna, Austria) and normalized
with the marray package41 by means of the Lowess normalization algorithm and then exported to BRB-ArrayTools.
Lowess intensity-dependent normalization was used to adjust for differences in labeling intensities of the Cy3 and
Cy5 dyes. The adjusting factor varied over intensity levels.42 Statistical analysis of biological replicates was performed using the significance analysis of microarrays algorithm43 with a two-class paired-unpaired design (control
lung vs. SuHx lung) and median centering to identify differentially expressed genes. The Δ value was chosen to
give an acceptable false discovery rate of <5%.
VEGF polymerase chain reaction (PCR) array
Rat VEGF RT2 Profiler PCR Arrays were used to analyze gene expression changes. Arrays and RT2 Real-Time
SyBR Green/ROX PCR Mix were purchased from SuperArray Bioscience (Frederick, MD). PCR was performed on
a Stratagene Mx3000P instrument (Stratagene, La Jolla,
CA), in accordance with the manufacturer’s instructions.
Lung samples from two normal and two SuHx rats were
compared. For data analysis, the ΔΔCt method was used
with the aid of a Microsoft Excel spreadsheet containing
algorithms provided by the manufacturer. Fold changes
were then calculated and reported as the SuHx/normal ratio
for each tissue type.

RES ULTS
Survey of expressed VEGF isoforms and VEGF
receptors in lung and heart tissues
Because treatment of rats with the VEGFR1 and VEGFR2
receptor blocker combined with chronic hypoxia generates angioobliterative PAH that is associated with accumulation of inflammatory cells, activation of inflammatory cells in the lungs, and activation of inflammatory
eicosanoid mediator–generating pathways,44 we postulated that the tissue expression profile of VEGF isoforms
and/or VEGF receptors would be altered because of inflammation or as a consequence of chronic VEGF receptor blockade. Lung tissue samples harvested from SuHx
rats 4 weeks after the initiation of the experimental protocol were surveyed, and the expression of VEGF ligand isoforms was assessed by Western blotting. Although there
was no significant change in the amount of VEGF-A and
VEGF-B expression, VEGF-C and VEGF-D expression was
increased; there was also a clear increase in expression
of the VEGFR3 protein (Fig. 1A–1F ). Figure 1H and 1 J
shows protein expression levels measured by ELISA of
the antiangiogenic sFlt-1 in the lungs and serum, respectively, in which we found a significant reduction in lung
tissue samples from SuHx rats and a trend toward an increase in serum from SuHx rats versus controls that did
not reach statistical significance.
To contrast the lung tissue expression with the expression profile of the dysfunctional RV, we assessed protein
expression in RV tissue samples from SuHx rats, again
using Western blotting. We found a significant reduction
in the expressed VEGF-A protein, confirming previous
results.35 A new finding was a reduction in the expressed
VEGF-B and VEGF-D proteins, which was not shared by
the RV tissues obtained from chronically hypoxic rats,
while the expression of VEGF-C trended toward a decrease in the RV tissue samples from SuHx rats without
reaching statistical significance (Fig. 2A–2E ). With IHC
staining, a clear reduction in VEGF-C from RV tissue of
SuHx compared with control rats was observed (Fig. 2F ).
As for serum samples from SuHx rats, the antiangiogenic sFlt-1 trended toward an increase in RV tissue samples compared with control animals (Fig. 2G).
To corroborate the tissue expression and localize the
expressed ligand and receptor proteins, we restricted the
remainder of our investigation to examine VEGF-C and
VEGFR3 expression in lung tissue samples. We found
expression of VEGF-C in bronchial epithelium of normal
rat lungs (Fig. 3A) but not in vascular endothelial cells.
In contrast, VEGF-C was expressed in endothelial cells
of muscularized pulmonary arterioles from SuHx rats
(Fig. 3A). The VEGFR3 protein was highly expressed in
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Figure 1. A, Lung tissue expression of the vascular endothelial growth factor (VEGF) isoform and of VEGF receptor proteins by
Western blot analysis. There is no change in the expression of VEGF-A and VEGF-B proteins, while VEGF-C and VEGF-D are
increased in expression in Sugen 5416/chronic hypoxia (SuHx) animals (B–E ). VEGFR3 protein expression is increased when
referenced to β-actin (G). The concentration of soluble VEGFR1 (sFlt-1) in the lung tissue is reduced (H ), while the sFlt-1 levels trended
toward an increase in the serum of SuHx animals (I ). SPARC protein expression is reduced in whole-lung tissue protein extracts from
SuHx rats ( J). Asterisks indicate P < 0.05. n ¼ 4. Hx: hypoxia-only rats.

cells of the lymph follicles (Fig. 3B) and in some of the
vascular endothelial cells from normal lungs, hypoxic lungs,
and SuHx lungs (Fig. 3A). In SuHx lungs, the cells surrounding vessel obliterating lesions and alveolar septal endothelial cells expressed VEGFR3 (Fig. 3A). Many of the
lumen-obliterating cells stained highly positive 3 weeks after
the start of the SuHx protocol.
We quantified VEGFR3þ cells in and around the pulmonary vessels in the lungs of SuHx rats and found that
the number of VEGFR3þ cells had more than doubled
by week 3 of the experimental protocol, while the number of VEGFR3þ lumen-obliterating cells was increased
at 3 weeks but not at 6 weeks (Fig. 3C). The reason why
VEGFR3 expression of lumen-obliterating cells is transient
is not clear.
To show coexpression of VEGFR3 with the endothelial cell marker (von Willebrand factor [vWF]), double immunofluorescence staining of VEGFR3 and vWF was done
for the lung tissue sections of control, hypoxia, and SuHx
rats (Fig. 4). There were VEFR3þ cells in and around the

lesions. In addition, there were several intimal, lumenfacing cells that express VEGFR3 but do not express vWF.
In larger control vessels we saw some orange cells, indicating that in large vessels there are some VEGFR3þ endothelial cells, and we speculate that these are precursor/
stem cells.

Microarray expression pattern of genes encoding
components of VEGF signal transduction in the
lungs of SuHx animals
The microarray gene expression pattern for normal lungs
and SuHx lungs (the animals had been killed at the end
of the Sugen plus 4-week hypoxic exposure) was analyzed
using published methodology45 and was focused on genes
encoding proteins involved in VEGF signaling, angiogenesis, and cell proliferation. Expressed genes were ranked according to their fold change compared with the expression
observed in normoxic lungs. The gene encoding phospholipase D (PLD) was 4.8-fold overexpressed, that encoding
early growth response 1 (Egr1) was 3.5-fold overexpressed,
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Figure 2. Proteins expressed in right ventricle (RV) tissues. All vascular endothelial growth factor (VEGF) isoform proteins are
reduced in expression in the RV of Sugen 5416/chronic hypoxia (SuHx) rats (A–E ). Immunohistochemistry (magnification, 10;
scale ¼ 50 μm) shows loss of staining in the SuHx RV tissues when applying an antibody specifically directed against VEGF-C (F ).
There is only a trend toward an increased concentration of the sFlt-1 protein in the SuHx RV. Asterisks indicate P < 0.05. n ¼ 4.
Hx: hypoxia-only rats.

that encoding endothelial cell nitric oxide synthase (eNOS)
was 2.6-fold overexpressed, and that encoding lysosomalassociated membrane protein 3 (Lamp3) was 5.7-fold overexpressed, while the gene encoding VEGFR2 showed significantly reduced expression (0.15), and SPARC (secreted
protein, acidic, and rich in cysteine, also known as osteonectin) expression was also reduced (0.26; Table 1). We
believe that these highly significant expression changes
are of importance in the context of angiogenesis and lung
vascular cell growth. It has been reported that VEGF stimulates PLD in endothelial cells via phospholipase C,46 and
pertinently PLD and VEGFR2 are colocalized in endothelial cell caveolae.47 Lamp3 was originally isolated from lung
tissue,48 and it is overexpressed in several cancers.49 Lamp3
is localized to endothelial Weibel-Palade bodies,50 and its
expression is increased by hypoxia.51

We confirmed the decreased expression of SPARC in
SuHx lungs by measuring lung tissue SPARC protein
expression (Fig. 1 J ). Kupprion et al.52 have shown that
SPARC inhibits the mitogenic effect of VEGF in microvascular endothelial cells, and there are multiple interactions between SPARC and VEGF signaling;53,54 SPARC
is induced by VEGF in vascular endothelial cells55 and
affects wound healing in a cell type–specific fashion.56

Treatment of SuHx rats with the VEGFR3 inhibitor
MAZ51 ameliorates the severity of pulmonary
hypertension and partially prevents lumen obliteration
Treatment of SuHx rats with every-other-day dosing of
MAZ51 reduced right ventricular systolic pressure (RVSP)
without affecting RV hypertrophy (Fig. 5A, 5B). However,
the number of fully obliterated pulmonary arterioles was

Figure 3. Immunohistochemistry of lung tissue sections (magnification, 40; scale ¼ 20 μm). Vascular endothelial growth factor
(VEGF)–C protein is expressed in bronchial epithelium in normal control lungs; in lungs of chronically hypoxic rats there is faint
staining of some cells of the adventitia, while arteriolar endothelial cells express VEGF-C in the lungs of Sugen 5416/chronic
hypoxia (SuHx) rats (A). VEGFR3 protein is expressed in endothelial cells in normal, chronically hypoxic, and SuHx animals and
in macrophages. VEGFR3 expression is found in bronchus-associated lymphoid tissue in large and small pulmonary artery
endothelial cells (B ). Luminal endothelial cells in SuHx animals express VEGFR3 at 3 weeks of the study protocol but not any
longer in the lungs of animals that had received Sugen 5416 and been exposed to chronic hypoxia and killed 6 weeks after the
Sugen 5416 implantation (C ). Asterisks indicate P < 0.05. n ¼ 4. Hx: hypoxia-only rats.
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Figure 4. Double immunofluorescence staining of vascular endothelial growth factor receptor 3 (VEGFR3) and von Willebrand factor (vWF) for lung tissue sections. Control and hypoxia
sections shows some of the endothelial cells of a medium vessel >50 μm expressing VEGFR3. The section from the Sugen 5416/chronic hypoxia (SuHx) rat lung shows abundant
VEGFR3 expression in and around the lesion. 4′,6-Diamidino-2phenylindole (DAPI) was used as a nuclear counterstain. Magnification, 40.

significantly reduced (Fig. 5D). In addition, the amount of
perivascular cell accumulation was significantly reduced,
and the BALT trended toward reduction without reaching
statistical significance (Fig. 5E, 5F). However, when SuHx
rats with established PAH and severe right heart dysfunction were treated with the VEGFR3 inhibitor MAZ51,32
the treatment resulted in worsening of PAH and right
ventricular hypertrophy (Fig. 6A, 6B ), and no changes
in vascular obliteration were observed when we screened
the lung sections (Fig. 6C), suggesting that blockade of
VEGFR3 adversely affected the function of the pressureoverloaded RV.

DISC US SION
In severe forms of angioproliferative PAH, inflammation
and precursor stem cells cooperate in presently incompletely understood mechanisms to respond to endothelial cell injury and apoptosis of pulmonary microvessel
cells.6,57-60 One hypothesis attempts to address the pathobiology of lung vascular remodeling by comparing it with
a quasi-neoplastic process or a process where the “vascular wound healing has gone awry.”1 Both of these concepts emphasize a disturbance of the homeostatic balance
that otherwise maintains a normal pulmonary microvessel
structure. One important vascular growth and maintenance factor is VEGF, as illustrated by the SuHx model of
severe PAH, which depends not on gene mutations but on
the actions of the antiangiogenic drug Sugen 5416. This
drug inhibits the critically important VEGF-dependent
growth and survival of endothelial cells, which the VEGF
protein transmits predominantly via VEGFR2, Akt, and
protein kinase C.21,59 While this mechanism of drug action
explains the initial endothelial cell apoptosis occurring in
the SuHx rat model,11 it does not explain the subsequent
proliferation of apoptosis-resistant endothelial cells60 or
the recently described bronchus-associated lymph follicle
formation.3,4
A recently published state-of-the-art review has discussed the SuHx model, stating that “whether VEGF inhibition promotes or inhibits PAH [is] creating confusion.”61 Unequivocally, the combination of Sugen 5416
plus chronic hypoxia in rats causes severe PAH, and a
recent report now describes profound and complicated
signaling changes that occur in endothelial cells as a consequence of prolonged VEGFR blockade.17 This publication now provides a conceptual framework for the understanding of the mechanisms whereby cells can escape
from antiangiogenic drug therapy.
To examine mechanisms of pulmonary microvessel proliferation following chronic hypoxic exposure combined
with VEGFR1 and VEGFR2 blockade, we measured the
expressed VEGF splice variants and demonstrated increased expression of the VEGFR3 protein in the lungs of
SuHx rats.62 VEGF isoforms are differentially expressed
in different organs and cells. For example, the highest
expression of VEGF-B is found in the developing myocardium,36 while VEGF-C is highly expressed in lymph vessels, T lymphocytes,63 and dendritic cells.64 We used Western blot technology to assess the amounts of expressed
proteins and thereafter IHC to identify and localize proteins in the lung tissue samples. Our data show that the
isoform pattern of VEGF and the expression of VEGFR3
is altered in the lungs of SuHx rats and that treatment
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of SuHx rats with the VEGFR3 inhibitor MAZ51 ameliorates the development of PAH in this model.
We recently reported increased expression of VEGFR3
and of inhibitor of differentiation 3 (ID3) in lung vascular
lesions of SuHx rats and showed in cultured endothelial
cells that Sugen 5416 increased expression of the transcription factors ID3, Oct-4, and Sox-2.62 ID3 is a transcription factor that is upregulated in its expression in
the pulmonary vasculature following chronic hypoxia.65
Of interest, the experimental overexpression of ID3 in
endothelial cells inhibits apoptosis and increases the expression of VEGFR3.58 Thus, these data are consistent with
the hypothesis that long-lasting Sugen 5416–triggered
VEGFR1 and VEGFR2 blockade can activate in endothelial
cells a stem cell–related cell proliferation mechanism62 that
includes VEGFR3 protein expression.
In the present experiments, we first assessed the tissue protein expression of the VEGF isoforms A, B, C, and
D using specific antibodies and Western blotting, and
we found that there is no significant change in VEGF-A
and VEGF-B protein expression in the lungs of SuHx
rats, while the expression of VEGF-C and VEGF-D was
increased compared with that in control lungs and
lungs from chronically hypoxic rats (Fig. 1). In addition,
there was increased expression of the VEGFR3 protein
(Fig. 1G).26
VEGFR3 is upregulated in the microvessels of tumors
and wounds as well as in angiogenic sprouts, and it has
been demonstrated that blockade of VEGFR3 signaling
with monoclonal antibodies decreased the sprouting in
angiogenic mouse models.29 In the context of the present investigation, it is important to point out that hypoxia induces the production of VEGF-C and increases the
expression of VEGFR3 in lymphatic endothelial cells.66
VEGFR3 is expressed in macrophages56 and is activated
by binding of VEGF-C and VEGF-D. It is therefore tempting to hypothesize that the angioproliferation in the lungs
of SuHx rats may also be driven by binding of the VEGFC and VEGF-D isoform ligands to VEGFR3 and signaling through the VEGFR3. We tested this hypothesis by
treating the SuHx animals with MAZ51, an inhibitor of
VEGFR3 (see below).32
To begin the investigation of gene expression changes
in the hypertensive SuHx lungs, we used microarray technology and focused on increased and decreased expression of genes encoding proteins involved in VEGF signaling and proteins that control cell growth. Interestingly,
the Sugen 5416–induced VEGFR1/VEGFR2 blockade in
the chronically hypoxic animals resulted in a profound
downregulation of the VEGFR2 gene. To our best knowl-
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edge, this is the first time it has been shown that inhibition of the VEGFR kinase results in a downregulation of
the gene encoding the VEGF receptor, suggesting a feedback mechanism between receptor function and receptor
gene expression. This finding was associated with downregulation of the SPARC gene and protein.
The diminished expression of the VEGFR2 gene in
combination with reduced SPARC expression are a manifestation of disturbed vascular cell homeostasis, as SPARC
can act in an antiangiogenic role by affecting signaling
through VEGFR2. Whether the overexpression of PLD reflects growth control signals that are routed by VEGF-C
through the VEGFR3 needs further investigation. The pattern of upregulated expression of Lamp3, PLD, and eNOS
and decreased expression of SPARC is characteristic of
cancer cell growth and metastasis.48,49,51,67,68
Treating rats from the start of the SuHx protocol with
MAZ51 ameliorated the developed PH and significantly
reduced the number of obliterated pulmonary arterioles
(Fig. 5), indicating to us that the elevated tissue levels of
the isoforms VEGF-C and VEGF-D are contributing via
VEGFR3 signaling to the process of lumen obliteration
and perivascular inflammation. This VEGFR3-dependent
mechanism is well established and has been recognized
to drive lymphatic vessel growth.69 VEGF-D serum protein levels have been measured and found to be elevated
in patients with lymphangiomyomatosis,70 but VEGF-C
or VEGF-D levels have not been reported in patients with
PAH.
As shown recently, the VEGFR3 inhibitor MAZ51 reduced PH in the monocrotaline model of PH.4 The authors treated rats with MAZ51 and demonstrated a reduced resistance vessel wall thickness, reduction of RV
hypertrophy, and a reduction in the mean PA pressure and
in the size of BALT in a prevention trial, but apparently
MAZ51 was less effective in a treatment trial. MAZ51, an
indolinone that blocks the ligand-induced autophosphorylation of VEGFR3, blocks the proliferation of VEGFR3expressing endothelial cells.32 Although Colvin et al.4 attributed the protective effect of MAZ51 treatment in the
monocrotaline PH model to BALT size reduction and
immune modulation, it is also plausible that the drug
blocks the growth of VEGFR3-expressing endothelial cells,
in particular in the abundant presence of the ligands
VEGF-C and VEGF-D—as is the case in the SuHx model
(Fig. 1D, 1E).
Intervention—that is, the treatment of SuHx rats with
established PAH—had no effect on the lung vessel obliteration, suggesting that VEGFR3-signaling contributes to
the development of pulmonary vascular remodeling but

Table 1. Gene expression changes in lungs of rats receiving Sugen 5416/chronic hypoxia (SuHx) treatment

Gene ID

Gene symbol

A_44_P321009

Cyp1a1

A_44_P191778

Cyp1b1

A_44_P251228

Cyp1b1

A_44_P304842

Tle1_predicted

A_44_P1050510

LOC686809

A_44_P476733

Nqo1

A_44_P448892

AA899841

A_44_P1052324

Lamp3

A_44_P323430

Nme7

A_43_P12736
A_44_P118475

Pld2
BX883043

A_44_P452245

Serpine1

A_44_P638176

LOC500152

A_44_P190088

Prpf39_predicted

A_43_P13102
A_44_P233080
A_44_P340236

Ada
Egr1
Clec4a1

A_44_P905727

TC628605

A_44_P100565
A_44_P368134

A_44_P100565
Sncaip_predicted

A_44_P570604

DN932947

A_44_P279452

AA957814

A_44_P198620

Nos3

A_42_P538400

Ntrk2

A_42_P812263

Sat

Description
Rattus norvegicus cytochrome P450, family 1, subfamily a, polypeptide 1
(Cyp1a1), mRNA [NM_012540]
Rattus norvegicus cytochrome P450, family 1, subfamily b, polypeptide 1
(Cyp1b1), mRNA [NM_012940]
Rattus norvegicus Sprague-Dawley cytochrome P450 (CYP1B1) mRNA,
complete cds [U09540]
PREDICTED: Rattus norvegicus transducin-like enhancer of split 1,
homolog of Drosophila E(spl) (predicted) (Tle1_predicted), mRNA
[XM_342851]
PREDICTED: Rattus norvegicus similar to protein 7 transactivated by
hepatitis B virus X antigen (LOC686809), mRNA [XM_001075804]
Rattus norvegicus NAD(P)H dehydrogenase, quinone 1 (Nqo1), mRNA
[NM_017000]
AA899841 UI-R-E0-cq-g-01-0-UI.s2 UI-R-E0 Rattus norvegicus cDNA clone
UI-R-E0-cq-g-01-0-UI 3′ similar to gi [AA899841]
Rattus norvegicus lysosomal-associated membrane protein 3 (Lamp3),
mRNA [NM_001012015]
Rattus norvegicus nonmetastatic cells 7, protein expressed in (Nme7),
mRNA [NM_138532]
Rattus norvegicus phospholipase D2 (Pld2), mRNA [NM_033299]
Rattus norvegicus chromosome 20, major histocompatibility complex,
assembled from 40 BACs, strain Brown Norway (BN/ssNHsd), RT1n
haplotype; segment 2/11 [BX883043]
Rattus norvegicus serine (or cysteine) peptidase inhibitor, clade E, member
1 (Serpine1), mRNA [NM_012620]
PREDICTED: Rattus norvegicus similar to multimerin 1 (LOC500152),
mRNA [XM_001071128]
AGENCOURT_17617267 NIH_MGC_236 Rattus norvegicus cDNA clone
IMAGE: 7128249 5′, mRNA sequence [CK472947]
Rattus norvegicus adenosine deaminase (Ada), mRNA [NM_130399]
Rattus norvegicus early growth response 1 (Egr1), mRNA [NM_012551]
Rattus norvegicus C-type lectin domain family 4, member a1 (Clec4a1),
mRNA [NM_001005890]
Q9D6B0_MOUSE (Q9D6B0) 18 days pregnant adult female placenta and
extra embryonic tissue cDNA, RIKEN full-length enriched library, clone:
3830420G05, product: G protein–coupled receptor 97, full insert
sequence, partial (13%) [TC628605]
Unknown
PREDICTED: Rattus norvegicus synuclein, alpha interacting protein
(synphilin) (predicted) (Sncaip_predicted), mRNA [XM_225768]
AGENCOURT_50134677 NCI_CGAP_Pr49 Rattus norvegicus cDNA clone
IMAGE: 7930540 5′, mRNA sequence [DN932947]
UI-R-E1-fz-b-03-0-UI.s1 UI-R-E1 Rattus norvegicus cDNA clone UI-R-E1-fzb-03-0-UI 3′, mRNA sequence [AA957814]
Rattus norvegicus nitric oxide synthase 3, endothelial cell (Nos3), mRNA
[NM_021838]
Rattus norvegicus neurotrophic tyrosine kinase, receptor, type 2 (Ntrk2),
mRNA [NM_012731]
Rattus norvegicus spermidine/spermine N1-acetyl transferase (Sat), mRNA
[NM_001007667]
110

Fold change
(SuHx/normal)
264.507
28.697
26.584
8.375

7.588
5.993
5.756
5.723
4.947
4.849
4.726

4.356
4.205
3.911
3.527
3.502
3.438
3.367

3.163
3.121
3.100
2.982
2.624
2.595
2.586

Table 1 (continued )

Gene ID

Gene symbol

A_43_P11686

Kdr

A_44_P778356
A_44_P120219

Hey2
AI177943

A_44_P527947

AA925093

A_44_P292689

Syt1

A_42_P817086

Scnn1b

A_42_P683634

Sparcl1

A_44_P181094

AI600081

A_44_P718743
A_44_P375102
A_44_P240274
A_44_P752342

TC648865
XM_214014
Emcn
BF563060

A_44_P206985

Gnrh1

A_44_P123492

Epb4.1l3

A_42_P556829
A_44_P229118

Wif1
Muc1

A_44_P405071

Cdk6

A_44_P937141

AW917120

A_44_P607972
A_44_P962361
A_43_P12613
A_42_P806859

TC593692
TC608677
Apln
AI229721

A_42_P469969

Igsf10

A_44_P983155

LOC292209

A_44_P409975

Wee1

Description
Rattus norvegicus kinase insert domain protein receptor (Kdr), mRNA
[NM_013062]
PREDICTED: Rattus norvegicus hairy [XM_344806]
AI177943 EST221594 Normalized rat placenta, Bento Soares Rattus sp.
cDNA clone RPLCI92 3′ end, mRNA sequence [AI177943]
UI-R-A1-ei-a-08-0-UI.s1 UI-R-A1 Rattus norvegicus cDNA clone UI-R-A1-eia-08-0-UI 3′, mRNA sequence [AA925093]
Rattus norvegicus partial mRNA for synaptotagmin 1 (syt1 gene), splice
variant 4 [AJ617619]
Rattus norvegicus sodium channel, nonvoltage-gated 1 beta (Scnn1b),
mRNA [NM_012648]
Rattus norvegicus SPARC-like 1 (mast9, hevin) (Sparcl1), mRNA
[NM_012946]
EST251784 Normalized rat embryo, Bento Soares Rattus sp. cDNA clone
REMDQ91 3′ end, mRNA sequence [AI600081]
Unknown
Rattus norvegicus similar to mac25 (LOC289560), mRNA [XM_214014]
Rattus norvegicus endomucin (Emcn), mRNA [NM_001004228]
UI-R-BO1-aiy-b-03-0-UI.r1 UI-R-BO1 Rattus norvegicus cDNA clone UI-RBO1-aiy-b-03-0-UI 5′, mRNA sequence [BF563060]
Rattus norvegicus gonadotropin-releasing hormone 1 (Gnrh1), mRNA
[NM_012767]
Rattus norvegicus erythrocyte protein band 4.1–like 3 (Epb4.1l3), mRNA
[NM_053927]
Rattus norvegicus Wnt inhibitory factor 1 (Wif1), mRNA [NM_053738]
Mucin 1 (fragment) [Source: Uniprot/SPTREMBL; Acc: O35770]
[ENSRNOT00000027850]
Cyclin-dependent kinase 6 (fragment) [Source: Uniprot/SPTREMBL; Acc:
Q99MD0] [ENSRNOT00000012597]
AW917120 EST348424 Rat gene index, normalized rat, norvegicus, Bento
Soares Rattus norvegicus cDNA clone RGIDZ48 5′ end, mRNA sequence
[AW917120]
Unknown
Unknown
Rattus norvegicus apelin, AGTRL1 ligand (Apln), mRNA [NM_031612]
AI229721 EST226416 Normalized rat embryo, Bento Soares Rattus sp.
cDNA clone REMCL08 3′ end, mRNA sequence [AI229721]
Rattus norvegicus immunoglobulin superfamily, member 10 (Igsf10),
mRNA [NM_198768]
PREDICTED: Rattus norvegicus similar to GTPase activating protein
testicular GAP1 (LOC292209), mRNA [XM_238066]
Rattus norvegicus wee1 homolog (S. pombe) (Wee1), mRNA
[NM_001012742]

Fold change
(SuHx/normal)
0.155
0.174
0.191
0.199
0.237
0.251
0.260
0.295
0.298
0.318
0.328
0.344
0.346
0.350
0.354
0.359
0.363
0.388

0.398
0.430
0.459
0.465
0.482
0.487
0.496

Note: Validation of gene expression changes is shown for 90 genes demonstrated by quantitative polymerase chain reaction
(PCR) analysis using the SABiosciences VEGF Signaling PCR Array. Those genes with statistically significant differences between
normal and SuHx lungs are given here (n ¼ 2, P < 0.05, t test). The average fold change (SuHx/normal) is shown for the most
differentially expressed genes.
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Figure 5. Concomitant treatment of Sugen 5416/chronic hypoxia (SuHx) rats with the vascular endothelial growth factor receptor 3
(VEGFR3) blocker MAZ51 reduced right ventricular systolic pressure (RVSP; A), the number of obliterated lung arterioles (C–D),
the degree of perivascular cell accumulation (E ), and the size of the bronchoalveolar lymph cell aggregate (F ). Asterisks indicate
P < 0.05. n ¼ (4 –7). Magnification, 10. Scale ¼ 50 μm. RV/LVþS: ratio of right ventricular weight to left ventricular plus septal
weight; BALT: bronchus-associated lymphoid tissue.

that the lesions, when established, cannot be reversed by
VEGFR3 blockade. Whether the worsening of RVSP by
MAZ51 treatment of established PAH points toward a
supportive role of VEGFR3 signaling in the failing heart
is unclear. Whereas we cannot find any publication reporting on VEGFR3 signaling in the heart, our data show
a dramatic reduction in VEGF-D and VEGF-B ligands
expression in the failing SuHx rat RV and a trend toward
reduced expression of VEGF-C (Fig. 2C–2E ). Hagberg
et al.71 have reported that VEGF-B controls endothelial cell fatty acid uptake, and Serpi et al.72 showed that
VEGF-B increased the growth of capillaries in rat left ventricles. Our present finding of reduced VEGF-B expression in the failing SuHx rat RVs complement previously

published data that show a multilevel impairment of fatty
acid oxidation in the SuHx RV tissues.34 Indeed, reduced
fatty acid transport across cardiac endothelial cells, as a
consequence of reduced VEGF-B expression, can perhaps
be an indicator of impaired myocardial endothelial cell
function in the failing RV. While the homeostatic role of
VEGF-A in the myocardium has been well established39
and inhibition of VEGF signaling has been shown to trigger myocardial hibernation,39 upregulation of the expression of soluble growth factor receptor 1 (sVEGFR1 or
sFlt-1) has been shown to prevent angiogenesis in the hypertrophied myocardium.73 We found that the sFlt-1 protein concentration in the serum and RV tissues trended
toward being increased in SuHx rats (Figs. 1I, 2G). Thus,
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Figure 6. Treatment of animals with established Sugen 5416/chronic hypoxia (SuHx)–triggered pulmonary hypertension with the
vascular endothelial growth factor receptor 3 (VEGFR3) inhibitor MAZ51 for 2 weeks worsened the degree of pulmonary hypertension when assessed by measurement of right ventricular systolic pressure (RVSP; A). In addition to the persistence of small
arteriole occlusion, the vessels appear highly muscularized (C ). Asterisks indicate P < 0.05. n ¼ 3. Magnification, 2.5. Scale ¼
100 μm.

the decreased expression of the ligand proteins VEGF-A,35
VEGF-B, and perhaps VEGF-D and VEGF-C, together
with high circulating levels of the antiangiogenic sFlt-1,
could all account for the capillary rarefaction of the failing SuHx rat RV and the metabolic remodeling of the RV
tissue.34 Table 2 lists the RV and lung tissue VEGF isoform
expression changes.
To summarize, the paradox that treatment of hypoxic
rats with the antiangiogenic VEGFR kinase blocker Sugen
5416 induces angioproliferation and lung vessel lumen
obliteration can in part be explained by a change in the
VEGF isoform ligand expression pattern and signaling
via VEGFR3. Both VEGF-C and VEGF-D could activate
VEGFR3 and cause endothelial cell proliferation.
This conclusion is supported by our data that demonstrate that blockade of VEGFR3, due to treatment of rats
with MAZ51, largely prevents pulmonary angiooblitera-

tion and perivascular cell infiltration in the SuHx model
of severe PAH, while treatment of animals with established pulmonary vascular lesions with MAZ51 does not
reopen vascular lesions but instead worsens the degree
of PAH and RV hypertrophy.
We emphasize that the roles of sFlt-1 in this model
need further investigation, in particular in view of the
reported high serum sFlt-1 levels in patients with IPAH.74
The second paradox that characterizes the SuHx rat
model is that the proliferative lung microangiopathy is
paired with the antiangiogenic environment of the failing RV.
Finally and again paradoxically, VEGF inhibition may
in the lungs both initiate endothelial cell apoptosis and
subsequently facilitate angioobliteration. We speculate that
in human forms of severe angioobliterative PAH endogenous antiangiogenic factors like sFlt-1 and endoglin70
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Table 2. Right ventricle (RV) and lung tissue vascular endothelial growth factor (VEGF) isoform expression changes
SuHx vs. control

VEGF-A
VEGF-B
VEGF-C
VEGF-D
VEGFR2
VEGFR3

Lung tissue

RV tissue

→
→
↑↑
↑↑
→
↑↑

↓↓
↓
↓
↓
NA
NA

Note: Shown are VEGF isoform and VEGF receptor protein
expression changes in Sugen 5416/chronic hypoxia (SuHx) lungs
and right ventricle tissue compared with controls. NA: not available.

may cause the initial endothelial cell death by inhibiting
VEGF-dependent cell survival and that VEGFR3-expressing
stem or progenitor cells62 may grow when the receptor is
activated by VEGF-C and/or VEGF-D.
Source of Support: This work was supported by funds from the
Victoria Johnson Center for Obstructive Lung Research.
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